LYCOS RETRIEVER 
Paxil: Studies
built 631 days ago
Recently, The New England Journal of Medicine released the results of a case-controlled study wherein Paxil was linked to an increased risk of an infant being born with Persistent Pulmonary Hypertension of the Newborn (PPHN). More specifically, the study showed that PPHN was six-times more common in infants whose mothers took an SSRI antidepressant during pregnancy compared to babies whose mothers did not take an antidepressant.
Source:
In one of the studies, the risk of heart defects in babies whose mothers had taken Paxil early in pregnancy was about 2 percent, compared to a 1 percent risk in the whole population. In the other study, the risk of heart defects in babies whose mothers had taken Paxil in the first three months of pregnancy was 1.5 percent, compared to 1 percent in babies whose mothers had taken other antidepressants in the first three months of pregnancy.
Source:
Two studies have shown that women who took Paxil during their first three months of pregnancy were 1.5-2 times as likely to have a baby with heart defects as women who were taking other antidepressants or women in the general population. The particular types of heart defects reported were holes in the walls of the chambers of the heart, knows as atrial and ventricular septal defects.
Source:
In June 2004, New York Attorney General Eliot Spitzer filed a lawsuit accusing GlaxoSmithKline (GSK) of burying several studies that indicated Paxil was ineffective in the treatment of children and adolescents and may increase suicidal thoughts. The lawsuit, filed in New York State Supreme Court... accuses Glaxo officials of misrepresenting data on the prescribing of Paxil to children.
Source:
Paxil should be continued as directed by the prescribing physician. Paxil is effective in the treatment of both short-term and long-term depression, and it can be beneficial in preventing relapse into depression. Studies have shown that Paxil is easily tolerated for up to four years. It is important to be in close communication with the prescribing physician, and to promptly report any unusual or distressing symptoms or side effects.
Source:
At the end of the six-month study, both Lexapro and Paxil were associated with improvement in anxiety symptoms. Mean changes in the Hamilton Rating Scale for Anxiety [HAM-A] scores from baseline to endpoint were -15.3 and -3.3, respectively. At endpoint, the overall mean daily doses of Lexapro and Paxil were 14.4 mg and 29.9 mg, respectively.
Source:
MORE ABOUT
Studies